Research project

ATTACK - Aspirin To Target Arterial Events in Chronic Kidney Disease

Project overview

Does low-dose aspirin reduce the chance of a first heart attack or stroke in patients with chronic kidney disease (CKD)?

This multicentre randomised trial will assess the effectiveness of low dose aspirin to prevent cardiovascular disease (CVD) in adult patients with chronic kidney disease(CKD). There is uncertainty about the benefits (vs CVD) and harms (bleeding) of aspirin in such patients. CKD is common and the frequency is rising and it is associated with increased risk of CVD.

Staff

Other researchers

Professor Joanne Lord

Director of SHTAC

Research interests

  • Joanne has research interests in health economic evaluation and decision modelling.
  • She has worked on a wide range of applied cost-effectiveness studies, including:
  • a review of newborn screening for inborn errors of metabolism;trials of diagnosis, patient education, structured decision-making and therapeutic interventions for arthritis and back pain;evaluations of diagnostic tests, preventive treatment and contact tracing for tuberculosis;a model of geographic allocation of resources for control of Chagas disease in Central America; andanalyses relating to the prevention and treatment of cardiovascular diseases. Her methodological contributions include an MRC funded project on whole pathway modelling for NICE clinical guidelines and an economic perspective on test evaluation. She has also contributed to health outcome and quality of life studies.
Connect with Joanne

Professor Simon Fraser BM MSc DM FFPH MRCGP FHEA DRCOG DCH

Professor

Research interests

  • Healthcare public health
  • Kidney disease
  • Multimorbidity
Connect with Simon

Collaborating research institutes, centres and groups

Research outputs

Hugh G. Gallagher, Mark Lown, Ahmet Fuat & Paul Roderick, 2019, British Journal of General Practice, 69(689), 590-591
Type: letterEditorial